関: macroprolactinoma、PRL-secreting pituitary adenoma、prolactin-secreting pituitary adenoma、prolactinoma

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

Utility of 11C-Methionine and 18F-FDG PET/CT in Patients With Functioning Pituitary Adenomas.

Feng Z1, He D, Mao Z, Wang Z, Zhu Y, Zhang X, Wang H.
Clinical nuclear medicine.Clin Nucl Med.2016 Mar;41(3):e130-4. doi: 10.1097/RLU.0000000000001085.
PURPOSE: MRI is commonly used in the evaluation of pituitary adenomas (PAs). However, it has difficulty to locate the lesions sometimes, especially microadenomas and/or postoperative recurrent tumors. We aimed to evaluate the role of combined C-methionine (MET) and F-FDG PET/CT in patients with func
PMID 26646998

Basu S1, Ranade R, Hazarika S.
Clinical nuclear medicine.Clin Nucl Med.2016 Mar;41(3):230-1. doi: 10.1097/RLU.0000000000001021.
Ga DOTATATE PET/CT in noninvasive characterization of synchronous pituitary neoplasm and meningioma in a 38-year-old man is illustrated. The patient presented with an MRI-detected lobulated enhancing sellar-suprasellar mass with erosion of bony sella measuring 4.5 × 3.5 × 3.4 cm (with differential
PMID 26462040

Tam AA1, Kaya C1, Başer H1, Ersoy R2, Çakır B2.
Archives of endocrinology and metabolism.Arch Endocrinol Metab.2016 Feb 16. pii: S2359-39972016005001101. [Epub ahead of print]
Objective Prolactin is a multifunctional pituitary hormone. The effect of prolactin on platelet activation is not well understood. Prolactinomas are the most common type of pituitary adenomas, and they are medically responsive to dopamine agonists. Mean platelet volume (MPV) is a marker of platelet
PMID 26886093

Evaluation of the Factors Predicting the Outcome of Transsphenoidal Microsurgery in Patients with Premenopausal Microprolactinoma

Comparison of the Effects of Cabergoline and Bromocriptine on Prolactin Levels in Hyperprolactinemic Patients

SABUNCU Tevfik,ARIKAN Ender,TASAN Ertugrul,HATEMI Husrev
Internal medicine 40(9), 857-861, 2001-09
… Patients Seventeen patients (7 with microprolactinoma, 4 with macroprolactinoma, 6 with idiopathic hyperprolactinemia) were given bromocriptine at a dose of 2.5 mg (or 5 mg for macroprolactinomas) twice daily, and 17 patients (8 with microprolactinoma, 4 with macroprolactinoma, 5 with idiopathic hyperprolactinemia) were given cabergoline at a dose of 0.5 mg twice weekly for 12 weeks. …
NAID 130000767432